BMY
Bristol-Myers Squibb Company
44.64
-
0.21
0.47%
18 x 44.70
12 x 0.00
bid
ask
1 @ 08:47 AM
44.70+0.06 (0.13%)
Bearish
42
Bullish
95
sentiment
44.53
day range
45.38
44.34
52 week range
69.10
Prev Close44.85
Open45.09
Low44.53
High45.38
Volume16.42M
Avg. Volume16.24M
Market Cap90.49B
Inst. Own79.01%
Beta0.39
Short Ratio1.99
Div & Yield2.40 / 5.35
EPS-3.10
P/E0.00
1yr Target50.09
50day MA50.93
200day MA54.11
CNQ.TO
Canadian Natural Resources Limited
106.83
04:00 PM
+
0.31
0.29%
G.TO
Augusta Gold Corp.
1.02
03:01 PM
+
0.06
6.25%
AAA.AX
BetaShares Australian High Interest Cash ETF
50.27
02:10 AM
+
0.01
0.02%
ACC.NS
ACC Limited
2531.80
06:00 AM
+
6.40
0.25%
600690.SS
Haier Smart Home Co., Ltd.
30.26
03:00 AM
+
1.46
5.07%
0700.HK
Tencent Holdings Limited
347.20
04:08 AM
-
0.40
0.12%
1101.TW
Taiwan Cement Corp.
32.05
01:30 AM
-
0.30
0.93%
20MICRONS.NS
20 Microns Limited
171.75
05:59 AM
-
0.90
0.52%
Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
News
...
Profile
...
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
Earning
...
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-04-25 | 2024-03 | -4.55 | -4.4 | 0.15 | 3.30% |
2024-02-02 | 2023-12 | 1.52 | 1.7 | 0.18 | 11.84% |
2023-10-26 | 2023-09 | 1.76 | 2 | 0.24 | 13.64% |
2023-07-27 | 2023-06 | 1.99 | 1.75 | -0.24 | -12.06% |
2023-04-27 | 2023-03 | 1.98 | 2.05 | 0.07 | 3.54% |
2023-02-02 | 2022-12 | 1.71 | 1.82 | 0.11 | 6.43% |
Upgrade / Downgrade
...
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-10-10 | Morgan Stanley | Upgrade | Underweight | Underweight |
2023-10-08 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-10-05 | Truist Securities | Upgrade | Buy | Buy |
2023-09-14 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-09-14 | TD Cowen | Upgrade | Market Perform | Market Perform |
2023-09-14 | Truist Securities | Upgrade | Buy | Buy |
Insider Holder
...
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-03-07 | BOERNER CHRISTOPHER S | Chief Executive Officer | 101.21K | Conversion of Exercise of derivative security |
2024-03-07 | CAFORIO GIOVANNI | Officer and Director | 432.27K | Conversion of Exercise of derivative security |
2024-03-07 | ELKINS DAVID VINCENT | Chief Financial Officer | 195.18K | Conversion of Exercise of derivative security |
2024-03-07 | GALLMAN CARI | Officer | 1.43K | Conversion of Exercise of derivative security |
2024-03-07 | HIRAWAT SAMIT | Officer | 60.28K | Conversion of Exercise of derivative security |
2024-03-07 | HOCH LYNELLE BAUMGARDNER | Officer | 1.73K | Conversion of Exercise of derivative security |
Institution Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Group Inc | 203.74M | 13.03B | 9.75% |
2023-06-29 | Blackrock Inc. | 172.67M | 11.04B | 8.27% |
2023-06-29 | JP Morgan Chase & Company | 103.31M | 6.61B | 4.95% |
2023-06-29 | State Street Corporation | 92.57M | 5.92B | 4.43% |
2023-06-29 | Capital International Investors | 69.30M | 4.43B | 3.32% |
2023-06-29 | FMR, LLC | 46.75M | 2.99B | 2.24% |
Fund Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 65.55M | 4.19B | 3.14% |
2023-06-29 | Vanguard 500 Index Fund | 50.02M | 3.20B | 2.39% |
2023-05-30 | Fidelity 500 Index Fund | 23.79M | 1.53B | 1.14% |
2023-08-30 | SPDR S&P 500 ETF Trust | 23.15M | 1.43B | 1.11% |
2023-08-30 | iShares Core S&P 500 ETF | 19.65M | 1.21B | 0.94% |
2023-06-29 | Vanguard Index-Value Index Fund | 18.25M | 1.17B | 0.87% |
Dividend
...
Dividend | Date |
---|---|
0.5 | 2024-05-06 |
0.6 | 2024-04-05 |
0.6 | 2024-04-04 |
0.6 | 2024-01-04 |
0.57 | 2023-10-05 |
0.57 | 2023-07-06 |
Split
...
Split | Date |
---|---|
1000000 : 951777 | 2001-08-07 |
1.05067 : 1 | 2001-08-06 |
2 : 1 | 1999-03-01 |
2 : 1 | 1997-03-03 |
2 : 1 | 1987-06-10 |
2 : 1 | 1983-05-27 |
This topic has been deleted. Only users with topic management privileges can see it.
-
-
When is the BLUE and BMY work complete as mentioned 45 days ago mid to end of July here.?
-
If you are in a pinch for money or know someone who is Robinhood is giving away a free share. If you know someone who is just getting started in the market its a great way to show them how to buy and sell with limits and stops with nothing invested. No monthly fees, and no commission fees.
-
Bristol Myers Squibb: Tough Times Continue (NYSE:BMY)
news.google.com • -
Bristol Myers Squibb: Tough Times Continue (NYSE:BMY)
news.google.com • -
PGGM Investments Takes Position in Bristol-Myers Squibb (NYSE:BMY)
news.google.com • -
Barclays Cuts Bristol-Myers Squibb (NYSE:BMY) Price Target to $43.00
news.google.com • -
Trend Tracker for (BMY)
news.google.com • -
2 Very Cheap Turnarounds Yielding Up To 7%
seekingalpha.com • -
Bristol-Myers Squibb (NYSE:BMY) Shares Up 1.4% After Earnings Beat
news.google.com • -
Bristol-Myers Q1 Loss Narrower Than Expected, Sales Beat
news.google.com • -
Is Bristol Myers Squibb Stock a Millionaire Maker?
news.google.com • -
Bristol Myers Squibb stock tumbles on cost-cutting initiative
news.google.com • -
Why Bristol Myers Squibb Stock Is Sinking Today
news.google.com • -
Why Bristol Myers Squibb Stock Is Sinking Today
news.google.com • -
Bristol-Myers Squibb Layoffs 2024: What to Know About the Latest BMY Job Cuts
investorplace.com • -
Bristol Myers Squibb (BMY) Q1 2024 Earnings Call Transcript
news.google.com • -
Is Bristol Myers Squibb Stock a Millionaire Maker?
news.google.com • -
Bristol-Myers stock drops amid plans to cut jobs (NYSE:BMY)
news.google.com • -
Merck jumps on profit beat as Bristol Myers Squibb slips to a loss
proactiveinvestors.com • -
Bristol Myers Squibb shares fall amid sluggish sales of some newer drugs
news.google.com • -
Bristol Myers: heavy quarterly loss on charges
news.google.com • -
Bristol-Myers stock falls despite Q1 beat (NYSE:BMY)
news.google.com • -
Bristol Myers: Q1 Earnings Snapshot
news.google.com • -
Bristol Myers posts quarterly loss, revenue rises 5%
reuters.com • -
Is Bristol Myers Squibb A Buy At These Bottom Levels?
seekingalpha.com • -
3 Undervalued Dividend Stocks to Buy Now to Beat the S&P 500
investorplace.com • -
3 Pharma Stocks That Are Money-Printing Machines in 2024
investorplace.com • -
6 Ultimate Dividend Stocks for Long-Term Passive Income Growth
247wallst.com • -
US biopharma first quarter earnings seen stable amid low expectations
proactiveinvestors.com • -
5 Relatively Secure And Cheap Dividend Stocks To Invest In - April 2024
seekingalpha.com • -
The 3 Most Undervalued Biotech Stocks to Buy in April 2024
investorplace.com • -
The Bargain Hunter's Dream: 3 Underpriced Stocks Poised for Massive Gains
investorplace.com • -
10 Dividend Growth Stocks: March 2024
seekingalpha.com • -
The 3 Best Biotech Stocks to Buy in Q2 2024
investorplace.com • -
Is Bristol Myers Squibb Stock a Buy?
fool.com • -
The Healthcare Bargain Blitz: 7 Undervalued Stocks to Inject into Your Portfolio
investorplace.com • -
2 More Potential Biotech Buyout Targets
seekingalpha.com • -
US FDA expands use of Bristol Myers' cancer therapy
reuters.com • -
Get Paid To Wait: 13 Potential Dividend Opportunities
seekingalpha.com •